Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx (Nasdaq: CDNA) announced that on July 30, 2026, it granted inducement equity awards to James McNally, the company’s newly appointed Executive Advisor. The award consists of 15,822 restricted stock units (RSUs) of CareDx common stock, granted as a material inducement to his employment.
According to CareDx, the RSUs were issued under the company’s 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). 50% of the RSUs are scheduled to vest on January 2, 2027 and the remaining 50% on July 2, 2027, subject to Mr. McNally’s continued service with CareDx through each vesting date.
CareDx (Nasdaq: CDNA) reported Q2 2026 revenue of $132 million, up 52% year-over-year, driven by Testing Services revenue of $100 million (+61%) on approximately 58,000 tests (+17%), Patient and Digital Solutions revenue of $19 million (+50%), and Lab Product revenue of $13 million (+8%).
According to CareDx, Q2 GAAP net income was $111 million versus a $9 million loss a year ago, including a $113 million gain on the June 30 sale of its Lab Products business to Eurobio Scientific. Non-GAAP net income was $20 million and adjusted EBITDA was $25 million versus $5 million in Q2 2025. The company raised 2026 revenue guidance to $490–$500 million (from $447–$465 million) and adjusted EBITDA guidance to $66–$78 million (from $43–$57 million). As of June 30, 2026, CareDx reported cash and cash equivalents of $374 million and stockholders’ equity of $426 million.
CareDx (Nasdaq: CDNA) announced it will report its second quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live and archived access available through the Events & Presentations section of its investor relations website.
CareDx (Nasdaq: CDNA) announced finalization of a Medicare Local Coverage Determination (LCD) for molecular testing used to detect solid organ allograft rejection in kidney, heart, and lung transplants. The final policy affirms and maintains coverage across CareDx’s transplant surveillance portfolio.
For AlloSure Kidney, Medicare will cover up to six surveillance tests in the first year post‑transplant and up to four tests per year in years two and three, with for‑cause testing unchanged. For AlloMap and AlloSure Heart, coverage is maintained, including combination use, with up to 12 surveillance tests in year one and four in years two and three. AlloSure Lung coverage is also maintained with up to 12 tests in the first year and four in years two and three. The Final LCD was published on July 16, 2026, and is expected to take effect on August 30, 2026.
CareDx (Nasdaq: CDNA) completed its acquisition of Naveris, adding the NavDx blood-based test for HPV-driven head and neck and anal cancers to its portfolio. NavDx is the first and only Medicare-covered MRD assay in these indications, with an ADLT Medicare rate of $1,800 and over 130,000 tests reported.
Naveris generated about $35 million revenue in 2025, more than doubling year-over-year. The deal expands CareDx’s estimated U.S. addressable market to over $12 billion across transplant, specialty oncology, and cell therapy. Naveris will be included in CareDx’s consolidated financial results beginning in Q3 2026.
CareDx (Nasdaq: CDNA) closed the previously announced sale of its Lab Products business to Eurobio Scientific on June 30, 2026, after Swedish regulatory clearance.
CareDx received $171.2 million in cash, and plans to focus on U.S. precision medicine testing services and patient and digital solutions, with more financial details expected on its Q2 2026 earnings call.
CareDx (Nasdaq: CDNA) will showcase its transplant precision diagnostics at the 2026 American Transplant Congress in Boston, June 20–24. More than 30 abstracts and 9 oral presentations feature AlloSure, AlloSure Plus, HistoMap Kidney, HeartCare, and ImmuneScape across kidney, heart, lung, and multiorgan transplantation.
CareDx (Nasdaq: CDNA) announced publication of a second KOAR analysis in the Journal of the American Society of Nephrology, evaluating AlloSure Kidney donor-derived cell-free DNA in 1,258 adult kidney transplant recipients across 56 U.S. centers.
Elevations in AlloSure dd-cfDNA were associated with higher adjusted hazards of allograft loss, often occurring before declines in kidney function, while persistently low levels correlated with favorable three-year outcomes. Findings support AlloSure Kidney as a noninvasive tool for longitudinal risk stratification and clinical decision-making in kidney transplantation.
CareDx (Nasdaq: CDNA), described as The Transplant Company and a leading precision medicine company for transplant patients, will join two investor events in June 2026.
Management will present at Jefferies and Goldman Sachs healthcare conferences, with live and archived webcasts on the CareDx investor relations site.
CareDx (Nasdaq: CDNA) announced that a 2021 qui tam action against the company has been dismissed by the U.S. District Court for the Eastern District of New York as of April 23, 2026, with no monetary payment required.
The dismissal follows the plaintiff’s request and Department of Justice concurrence. The case, filed February 12, 2021, led to a DOJ investigation that, according to CareDx, concluded on October 8, 2024 without any finding of wrongdoing. CareDx has consistently denied allegations of wrongdoing.